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B lymphocytes perform somatic hypermutation and
class-switch recombination (CSR) of the immuno-
globulin locus to generate an antibody repertoire
diverse in both affinity and function. These somatic
diversification processes are catalyzed by activa-
tion-induced cytidine deaminase (AID), a potent DNA
mutator whose expression and function are highly
regulated. Herewe show that AIDwas regulatedpost-
transcriptionally by a lymphocyte-specificmicroRNA,
miR-155. We found that miR-155 was upregulated in
murineB lymphocytes undergoingCSRand that it tar-
geted a conserved site in the 30-untranslated region of
the mRNA encoding AID. Disruption of this target site
in vivo resulted in quantitative and temporal deregula-
tion of AID expression, along with functional conse-
quences for CSR and affinity maturation. Thus, miR-
155, which has recently been shown to play important
roles in regulating the germinal-center reaction, does
so inpartbydirectly downmodulatingAIDexpression.
INTRODUCTION
Vertebrates are able to produce a vast repertoire of antibody
molecules to combat infection. The number of antibody specific-
ities available during a human lifetime is estimated to exceed 109,
far greater than the coding capacity of the genome. Instead, the
size of the antibody repertoire results from gene-diversification
processes that occur in antibody-producing B lymphocytes.
During B cell development, antibody genes are assembled by
DNA rearrangement [V(D)J recombination] to produce the pri-
mary repertoire of antibody specificities (about 105–106 different
specificities). However, this repertoire is neither large enough nor
specific enough to include high-affinity antibodies against the full
range of antigens an animal might encounter. Thus, the genera-
tion of antibody diversity depends largely on processes that
follow V(D)J recombination.
Two main processes drive the generation of the secondary
antibody repertoire: somatic hypermutation [or SHM, wheremutations are introduced in and around the productively rear-
ranged V(D)J segment] and gene conversion (or GCV, where
nonfunctional pseudogenes are used as templates for diversifi-
cation). Both SHM and GCV are triggered by activation-induced
cytidine deaminase (AID), an enzyme believed to function di-
rectly as a DNA mutator. In addition to these two processes,
AID-mediated deamination initiates class switch recombination
(CSR), a reaction that does not contribute to diversification of an-
tibody specificity but replaces the default Ig constant region (Cm)
with a downstream constant region (Cg, C3 or Ca) to alter the
effector capacity of the antibody while retaining the specificity
for antigen (Teng and Papavasiliou, 2007).
A potent mutator such as AID must be stringently regulated in
the cell. Indeed, it has been proposed that AID is regulated tran-
scriptionally (Dedeoglu et al., 2004; Gonda et al., 2003; Sayegh
et al., 2003), by intracellular compartmentalization and trafficking
(Ito et al., 2004; McBride et al., 2004), by posttranslational mod-
ification (Basu et al., 2005; Basu et al., 2007; McBride et al.,
2006; Pasqualucci et al., 2006), and by interaction with specific
cofactors (Chaudhuri et al., 2004; MacDuff et al., 2006). In addi-
tion to these more traditional modes of regulation, we show here
that AID is also subject to posttranscriptional regulation by a
specific microRNA, miR-155.
miR-155 belongs to a recently identified class of noncoding
21–23 nt RNAs that function as posttranscriptional modulators
of gene expression. Encoded by diverse metazoan genomes,
miRNAs target their cognate messenger RNAs for degradation
or translational repression (Bartel, 2004; Bartel and Chen,
2004). Their functional influence is apparent in a host of biologi-
cal processes, ranging from pancreatic insulin secretion (Poy
et al., 2004) to B and T cell development (Zhou et al., 2007).
miR-155 is processed from the noncoding RNA transcribed
from Bic (B cell integration cluster); this RNA serves as the pri-
mary miRNA precursor.Bicwas originally identified as a common
site for insertion of proviral DNA in lymphomas induced by
the avian leukosis virus (Tam et al., 1997). A role for miR-155 in
germinal-center development and function has recently been
proposed on the basis of studies using in vivo loss-of-function
and gain-of-function approaches to analyze the consequences
of deletion or ectopic expression of miR-155, which revealed B
cell autonomous defects in affinity maturation (Rodriguez et al.,
2007; Thai et al., 2007). However, miR-155 has been shown toImmunity 28, 621–629, May 2008 ª2008 Elsevier Inc. 621
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miR-155 Negatively Regulates AIDFigure 1. miR-155 Is Upregulated in B Cells
Undergoing CSR and Targets the 30 UTR of
AID mRNA
(A) Relative cloning frequencies for ten of the most
abundant miRNAs in murine splenic B lympho-
cytes stimulated with IL-4 and LPS (0, 8, 24, 48,
and 72 hr). The color-coding scale is shown at bot-
tom, and undetected miRNAs are indicated by
black.
(B) RNA blots for miR-155 from total RNA isolated
from murine splenic B cells (left) and the murine
B cell line CH12-F3 (right), stimulated in vitro
(0–72 hr) to undergo CSR. Ethidium-bromide stain-
ing of tRNA bands is shown as a loading control.
(C) Base pairing between murine miR-155 (itali-
cized) and its target site in the wt AID 30 UTR.
Sequences of the mutated (mut-UTR) and deleted
(del-UTR) target-site variants are shown under-
neath.
(D) CH12-F3 cells stimulated to undergo CSR were
transfected with reporter constructs containing
firefly luciferase alone (Luc) or fused to the wild-
type AID 30 UTR (UTR), del-UTR, or mut-UTR.
Data represent mean values of eight independent
experiments ± standard error of the mean (SEM).
One-way ANOVA F statistic = 2.95 (p = 0.05).target more than 60 different genes in B cells (Vigorito et al.,
2007), and it is unclear which of those genes would be directly
targeted by this microRNA to produce the observed phenotype.
Furthermore, induction of miR-155 expression has been found in
association with the activated phenotype of several types of im-
mune cells, including T lymphocytes, dendritic cells, and macro-
phages (O’Connell et al., 2007; Rodriguez et al., 2007; Thai et al.,
2007), suggesting synergistic action of miR-155 on numerous
target genes in multiple cell types.
Here we present evidence that AID is a direct target for miR-
155 regulation in vivo. Using a bacterial artificial chromosome
(BAC) transgenic model of AID expression, we show that specific
ablation of miR-155:AID interaction deregulates AID protein
expression in germinal-center B cells and results in ectopic per-
sistence of AID expression in B cells as they exit the germinal
centers and enter the peripheral circulation. We also show that
lack of AID regulation by miR-155 leads to defective affinity mat-
uration. Hence, the central role of miR-155 in control of the
germinal-center reaction (Thai et al., 2007) is at least in part
due to its role in repression of AID expression.
RESULTS
miR-155 Is Upregulated in B Cells Undergoing
Class-Switch Recombination
microRNAs (miRNAs) comprise a class of newly discovered
small RNA species that regulate gene expression. To investigate
the role these regulators might play in CSR, we cloned and
sequenced miRNAs present in primary B cells before and after
stimulation with LPS and IL-4, conditions that induce switching
from IgM to IgG1. Of the 123 miRNAs that were cloned from
these samples (data not shown), we identified one, miR-155,
that was upregulated after stimulation (Figure 1A). Importantly,
miR-155 was upregulated not only in primary B cells treated
with LPS and IL-4 but also in CH12-F3 cells, a murine B cell622 Immunity 28, 621–629, May 2008 ª2008 Elsevier Inc.line that switches from IgM to IgA after treatment with anti-
CD40, IL-4, and TGF-b (Figure 1B). Thus, miR-155 is upregulated
during CSR in a manner that is not isotype specific.
miR-155 Can Target the 30 UTR of AID mRNA
We applied several miRNA target-prediction algorithms [PicTar
(Krek et al., 2005), miRanda (Griffiths-Jones et al., 2006; John
et al., 2004), and TargetScan (Grimson et al., 2007; Lewis et al.,
2003)] to identify putative targets of miR-155 with relevance to
either SHM or CSR. AID was consistently predicted as one
such target. Depending on the algorithm used, a number of addi-
tional miRNA binding sites in the AID mRNA were identified (not
shown); however, these miRNAs were not detected in switching
B cells by cloning or by RNA blot. Furthermore, the stringent pre-
diction criteria of the most recent version of the TargetScan algo-
rithm (Grimson et al., 2007) identified miR-155 as the sole miRNA
target site in the AID 30 UTR. The 30 UTRs of AID mRNA diverge
substantially in sequence and length between various species
(Figure S1 in the Supplemental Data available online). However,
they coincide strikingly at an 8 nt motif corresponding to the
predicted miR-155 target-site seed region. To test the possibility
of posttranscriptional AID regulation by miR-155, we created
reporter constructs containing the 30 UTR of Aicda downstream
of a firefly luciferase reporter gene (Luc-UTR), along with variants
harboring deletion (Luc-del-UTR) or mutation (Luc-mut-UTR) of
the miR-155 target site (Figure 1C). These constructs were tran-
siently transfected into CH12-F3 cells stimulated to undergo
CSR (and hence induced to express endogenous miR-155).
We observed repression of luciferase activity by 50% in Luc-
UTR-transfected cells compared to cells transfected with a lucif-
erase-only construct (Figure 1D). This repression was alleviated
upon disruption of the miR-155 target site by deletion or muta-
tion. These data indicate that the single target site in the 30
UTR of the AID mRNA renders it susceptible to repression by
physiological levels of miR-155 expressed during CSR.
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miR-155 Negatively Regulates AIDFigure 2. Mutation of the AID miR-155
Target Site Results in Deregulated AID-GFP
Expression and Increased CSR Efficiency
In Vitro
(A) AID-GFP mRNA expression was monitored by
quantitative PCR in representative Aicda-Gfp con-
trol (gray) and Aicda-Gfp-Mut (black) mice. Data
are normalized to Ku70 mRNA expression, and
the scale is set to 1 for d0.
(B) AID-GFP protein expression was monitored
by FACS up to 4 days after in vitro stimulation of
splenic B lymphocytes with IL-4 and LPS. Per-
centages of GFP+ B220+ cells are indicated in
the upper right quadrants. Cells from representa-
tive Aicda-Gfp control (Tg copy number approxi-
mately 5) and Aicda-Gfp-Mut (Tg copy number
approximately 5) are shown.
(C) Median GFP fluorescence intensities, ex-
pressed in logarithmic units, are shown for the
Aicda-Gfp (gray) and Aicda-Gfp-Mut (black) sam-
ples in (B).
(D) Splenic B lymphocytes from wild-type (n = 4);
Aicda+/, Aicda-Gfp control (n = 5); Aicda/,
Aicda-Gfp control (n = 2); Aicda+/, Aicda-Gfp-
Mut (n = 6), or Aicda/, Aicda-Gfp-Mut (n = 3)
mice were stimulated in vitro for 3 days with LPS
(for inducing CSR to IgG3), LPS and IL-4 (for in-
ducing CSR to IgG1), or LPS and IFNg (for induc-
ing CSR to IgG2a). Data represent mean values ±
SEM. Note that Aicda/, Aicda-Gfp control
samples did not switch robustly to IgG1 or IgG3,
although IgG1+ and IgG3+ populations were
detected by FACS analysis (data not shown), but
they did show quantifiable levels of CSR to
IgG2a. t tests, *p < 0.05, **p < 0.01.Mutation of the Aicda miR-155 Target Site Results
in Deregulated AID Expression and Increased CSR
in Splenic B Cells Stimulated In Vitro
To study the behavior of in vivo AID expression in response to
miR-155, we took advantage of a recently generated transgenic
Aicda-Gfp indicator mouse strain (Crouch et al., 2007). These
mice carry between two and ten copies of a 75 kb BAC that con-
tains the entire Aicda locus as well as its two adjacent gene loci
(Mfap5 and Apobec1). The Aicda locus in this BAC has been
modified such that the gene encoding GFP is inserted down-
stream of the coding portion of the final Aicda exon (Figure S2A).
The transgenic AID-GFP fusion protein expressed from this BAC
was previously shown to replicate endogenous patterns of AID
expression (Crouch et al., 2007). The AID-GFP gene product
also retains catalytic activity; it can rescue CSR in Aicda/ B
lymphocytes in vitro (Figure S2B). Based on this published
Aicda-Gfp BAC, we created a second transgenic construct in
which the miR-155 target-site seed region was mutated to dis-
rupt binding to miR-155 (Aicda-Gfp-Mut) (Figure S2A). We
used this second construct to generate five independent founder
lines carrying the Aicda-Gfp-Mut BAC transgene (founders car-
ried varying copy numbers of the transgene, ranging from 5–20).
Splenic B lymphocytes from progeny of these transgenic
founders were analyzed for AID-GFP expression in response
to IL-4 and LPS stimulation in vitro. The dynamics of AID-GFPexpression differed considerably between the Aicda-Gfp control
and Aicda-Gfp-Mut mice. The controls exhibited a gradual in-
crease of low-intensity AID-GFP fluorescence with time of stim-
ulation [as also observed by (Crouch et al., 2007)]; this expres-
sion profile mirrored that of endogenous AID. In contrast, cells
from Aicda-Gfp-Mut mice showed a rapid AID-GFP induction,
peaking early around day 3, then reaching a plateau (Figures
2A and 2B). The median intensity of AID-GFP fluorescence
was also higher in the Aicda-Gfp-Mut mice, suggesting more
abundant AID-GFP protein than in controls (Figure 2C).
These disparities were not due to position effects resulting
from differential integration of each BAC transgene because (1)
large BACs such as this are not susceptible to overexpression
due to random insertion in active expression sites (Gong et al.,
2003; Hatten and Heintz, 2005) and (2) we have screened multi-
ple independent Aicda-Gfp-Mut founder lines with identical
results (Figure S3). In addition, these differences were not a result
of AID-GFP overexpression due to copy number variation
between the two BAC transgenics because we have screened
animals with similar copy numbers and obtained identical results
(Figure S3). Therefore, our results demonstrate that in vivo dis-
ruption of the AID miR-155 target perturbs the quantitative and
temporal expression characteristics of AID.
To assess the functional consequences of disruption of
the miR-155 target site, we bred the Aicda-Gfp control andImmunity 28, 621–629, May 2008 ª2008 Elsevier Inc. 623
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the contribution of endogenous AID. We first compared in vitro
CSR efficiency by stimulating splenic B lymphocytes from these
mice by using LPS (to induce CSR to IgG3), both LPS and IL-4
(to induce CSR to IgG1), or both LPS and IFNg (to induce CSR
to IgG2a). Aicda/ B cells perform negligible in vitro CSR
(data not shown). We observed increased CSR in the Aicda-
Gfp-Mut mice compared to Aicda-Gfp control or wild-type
mice (Figure 2D). This was the case regardless of whether these
BAC transgenics were deficient or heterozygous for Aicda in
the endogenous locus (Figure 2D). These results indicate that
miR-155 directly regulates AID expression in stimulated B
lymphocytes.
Mutation of the miR-155 Target Site Leads
to Local but Not Global Deregulation of AID In Vivo
To study in vivo effects of disrupting the AID miR-155 target site,
we immunized the transgenic mice intraperitoneally with nitro-
phenol conjugated to chicken gamma globulin (NP-CGG). The
NP hapten induces a well-characterized immune response
(Cumano and Rajewsky, 1985; Furukawa et al., 1999; Taketani
et al., 1995) in peripheral lymphoid germinal centers (GC), micro-
environments where activated lymphocytes undergo Ig diversifi-
cation. Eighteen to 21 days after immunization, we evaluated
Figure 3. NP-Immunized Aicda-Gfp-Mut Mice Do Not Express
AID-GFP in Developing B Lymphocytes or in T Lymphocytes
FACS analyses are shown for representative Aicda-Gfp and Aicda-Gfp-Mut
mice.
(A) Developing B cells (CD93+) from the bone marrow are subdivided into pro-
and pre-B cells (box 1: IgM, B220low), transitional B cells (box 2: IgM+,
B220low), and recirculating B cells (box 3: IgM+, B220high). Histograms for
GFP fluorescence show pro- and pre-B cells (red), transitional B cells (blue),
and recirculating B cells (black).
(B) CD8+ and CD4+ T lymphocytes from thymus and peripheral blood are
shown.624 Immunity 28, 621–629, May 2008 ª2008 Elsevier Inc.AID-GFP expression by FACS in various B lymphocyte subsets.
Mutation of the miR-155 target site did not disrupt global tran-
scriptional control of AID: Immature CD93+ B lymphocytes in
the bone marrow, along with thymic and peripheral CD4+ or
CD8+ T lymphocytes, were devoid of AID-GFP (Figure 3). How-
ever, AID-GFP was detected in B cell populations associated
with activation. GC B lymphocytes (CD95+ B220+) from spleen
and intestinal Peyer’s patches expressed AID-GFP in both the
control and Aicda-Gfp-Mut mice. The latter, however, showed
far more intense GFP fluorescence, indicating a similar over-
abundance of AID-GFP during the GC reaction, as observed
during in vitro CSR (Figure 4A).
Figure 4. Mutation of the AIDmiR-155 Target Site Results in Deregu-
lated In Vivo Expression of AID-GFP in NP-CGG Immunized Mice
(A) FACS analyses for AID-GFP expression in GCs from representative Aicda-
Gfp and Aicda-Gfp-Mutmice. (Left) GC B cells from Peyer’s Patches (gated on
B220+ B cells). (Right) Histograms show AID-GFP expression in B cell subsets
from GCs of Peyer’s patches (PP) and spleen. Shown in overlay are CD95+
B220+ GC B cells (blue) and the subset of GC B cells that recognize NP (red).
(B) FACS analyses for AID-GFP expression in peripheral blood from represen-
tative Aicda-Gfp and Aicda-Gfp-Mut mice. (Left) Total blood lymphocytes are
shown. (Right) Histograms show AID-GFP expression in IgM-IgD+, B220+
(cyan) and IgG1+, B220+ (blue) B cell subsets. Red overlays indicate the re-
spective subsets that recognize NP (note that the blue and red overlays in
the IgG1+ histogram overlap completely).
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miR-155 Negatively Regulates AIDFigure 5. Aicda-Gfp-Mut Mice Show Loss of Affinity Maturation
Shown from left to right are average titers of NP3-binding IgG1, NP30-binding IgG1, and NP3:NP30 binding ratios as measured by ELISA on day 8 (gray) or day 19
or 21 (black) after immunization in Aicda-Gfp (n = 3) and Aicda-Gfp-Mut (n = 7) mice ± SEM. t test, *p = 0.0016.After completing the GC reaction, activated B lymphocytes
exit into the periphery and differentiate into plasma or memory
cells. These post-GC B lymphocytes have been shown to cease
expression of AID (Crouch et al., 2007). Accordingly, the Aicda-
Gfp control mice did not express AID-GFP in B cells in the
peripheral blood (Figure 4B). In contrast, a GFP+ population of
B cells was consistently detected in the blood of immunized
Aicda-Gfp-Mutmice (Figure 4B). These appeared to be a hetero-
geneous population of B lymphocytes (B220int-hi), which were
mostly IgG1+ but also included IgM+ and IgD+ nonswitched cells.
This B lymphocyte population did not appear to arise ectopically
as a consequence of AID-GFP overexpression; a similar B220int
(though GFP) population was also present in the Aicda-Gfp
controls. Thus, disruption of the AID miR-155 target site allows
for improper persistence of AID-GFP expression beyond the
GC compartment. These results confirm once again that the
phenotypes we observed cannot be explained by variation in
BAC copy number, which could be expected to increase protein
expression but cannot lead to persistent expression in cells
where the gene of interest is normally shut off. Thus, our data
strongly support the idea that miR-155 controls AID expression
levels and, specifically, plays a pivotal role in extinguishing AID
expression in post-GC B cell populations.
Loss of miR-155 Regulation of AID Results
in Impaired Affinity Maturation
To determine the functional impact of defective AID downregula-
tion, we compared affinity maturation (increased antibody affin-
ity achieved through SHM) of NP-binding IgG1 in sera collected
at 8 days and 19 or 21 days after immunization. The ELISA cap-
ture substrate was NP conjugated to BSA in different ratios
to detect high-affinity (NP3-BSA) and total (NP30-BSA) immuno-
globulins (Ig) specific for NP. Affinity maturation was measured
as the NP3:NP30 binding ratio. As expected, we observed an in-
crease in the proportion of high-affinity Ig from day 8 to day19 or
21 in control Aicda-Gfp mice. However, affinity maturation was
significantly impaired in Aicda-Gfp-Mut animals (Figure 5).
To ascertain whether the observed affinity-maturation defect
resulted from AID-GFP overexpression in GC’s, we analyzed
the mutation load at Ig loci in CD95+ GC B lymphocytes. After se-
quencing the VH186.2 gene segment that is selected for duringthe Ig response against NP (Cumano and Rajewsky, 1985) (to as-
sess the mutation profile under selection) and the JH4 intron (to
assess the mutation profile in the absence of selection pressure),
we found that the frequencies and overall patterns of mutation
did not differ substantially between Aicda-Gfp and Aicda-Gfp-
Mut mice (Table 1). Thus, we considered two possibilities: Either
the repair mechanisms that process AID-mediated lesions are
not overwhelmed by higher lesion loads, or excess AID was
not specifically targeted to the Ig locus.
Aside from the Ig genes, a number of other genes, including
the oncogene Bcl6, have been shown to hypermutate in the ger-
minal centers (Pasqualucci et al., 2001; Shen et al., 1998).
We reasoned that excess AID mutational activity, if not targeted
to the Ig genes, could instead be targeted to these other non-Ig
loci. To test this hypothesis, we cloned and sequencedBcl6 from
GC B lymphocytes of NP-immunized Aicda-Gfp and Aicda-Gfp-
Mut mice. We found that Bcl6 from Aicda-Gfp GC B cells was
mutated with a frequency of 0.17 3 103 per base [similar to re-
ported Bcl6 mutation frequency in murine GC B cells from
Peyer’s Patches (Muto et al., 2006) (Table 1)]. In contrast, Bcl6
from Aicda-Gfp-Mut GC B lymphocytes mutated about three
times as frequently (0.46 3 103 per base) (Table 1). This obser-
vation supports the hypothesis that excess AID activity within the
GC is distributed to non-Ig targets for hypermutation and raises
the possibility that loss of miR-155-mediated downregulation of
AID could result in higher rates of AID-dependent translocation
or lymphomagenesis.
Table 1. Mutation Frequencies 3 103 per Base
Genotypea VH186.2 JH4 Intron Bcl6
Aicda-Gfp 31.8 6.8 0.17
(394/12,400)b (79/11,600) (7/41,600)c
Aicda-Gfp-Mut 30.7 5.5 0.46
(800/26,000) (101/18,400) (18/39,000)
Mutation frequencies (accumulated number of mutations in a given
region divided by the total number of nucleotides sequenced from that
region) are shown for VH186.2, the JH4 intron, and Bcl6 from splenic
GC B cells in NP-immunized Aicda-Gfp and Aicda-Gfp-Mut mice.
a Mutation data are pooled from two animals.
b Number of point mutations/total nucleotides sequenced.
c Chi square test, p = 0.0306.Immunity 28, 621–629, May 2008 ª2008 Elsevier Inc. 625
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ration observed in the Aicda-Gfp-Mut mice. We then asked
whether continued mutation outside of the GC (as a result of per-
sistent AID-GFP expression in post-GC B cells) could account for
this phenotype. To test this possibility, we cloned and sequenced
the JH4 intron from post-GC lymphocytes from peripheral blood
of Aicda-Gfp and Aicda-Gfp-Mut mice. We found that B lympho-
cytes from the blood of Aicda-Gfp mice comprised a small num-
ber of highly related and affinity-matured clones, with some intra-
clonal heterogeneity (Table 2). This is not surprising because
post-GC B cell clones in the blood have undergone stringent pos-
itive selection for those producing high-affinity Ig. In contrast, we
found a higher number of unique post-GC B lymphocyte clones in
the blood of Aicda-Gfp-Mut animals. Because these clones were
so heterogeneous, we could not conclusively ascertain whether
the mutational load per unique clone was higher in comparison
to those from the bloodofAicda-Gfpmice (i.e.,whether thesecells
were continually mutating their JH4 intron). However, inagreement
with the serum data, these clones did not appear to have acquired
the amino acid substitutions associated with high-affinity NP an-
tibodies [notably, the W33L substitution or the Y99G substitution
(Furukawa et al., 1999)]. Thus, it did not appear that these clones
emerged from the germinal center with high affinity, which would
then be lost as a result of continuing mutation; rather, it appeared
that persistent AID expression led to escape from the germinal
center of cells bearing low-affinity NP antibodies.
DISCUSSION
Although hundreds of miRNAs are present in the mammalian ge-
nome, genetic studies addressing their physiological roles are at
an early stage. In the present work, we address the function of
miR-155 in the context of antibody diversification by identifying
this particular miRNA as upregulated in B cells stimulated to
undergo CSR, by bioinformatically identifying AID as a putative
target, and by genetically mutating the target sequence in the
30 UTR of the AID mRNA to allow the gene to escape miR-155
control. These experiments identify a target of a miRNA in vivo
by manipulating not the expression of the miRNA itself but rather
by genetically disrupting the association between a miRNA and
its putative target gene.
Most genes contain multiple predicted target sites for several
different miRNAs. Deletion of just one of these targeting miRNAs
can result in protein upregulation in a dose-dependent manner,
Table 2. Clonal Variability in Post-GC B Cells
Genotypea
Number of Unique
Clones/Total
Intraclonal Mutation
Frequency 3 103
Percent
W33L
or Y99Gd
Aicda-Gfp 9/50c 0.55 (11/20,000)b 63
Aicda-Gfp-Mut 36/80c 0.87 (34/39,000) 18
Clonal variability of post-GC lymphocytes in Aicda-Gfp and Aicda-Gfp-
Mut mice is shown in terms of clonal mutations in the JH4 intron and
amino acid substitutions associated with NP antibody affinity maturation.
a Mutation data represent unique clones pooled from four animals.
b Number of point mutations/total nucleotides sequenced.
c Fisher’s exact test for the indicated data sets, p = 0.043.
d W33L and Y99G are substitutions associated with high affinity.626 Immunity 28, 621–629, May 2008 ª2008 Elsevier Inc.leading to the hypothesis that multiple microRNAs synergistically
fine-tune the expression of a single target gene (Xiao et al., 2007).
Surprisingly, the AID 30 UTR is predicted to contain only one
miRNA target site, binding miR-155. We have shown that muta-
tion of the seed region of this site leads to dramatic protein over-
abundance and disruption of proper temporal protein downregu-
lation. We do not exclude the possibility that the specific point
mutations introduced at the miR-155 target site could result
in additional miR-155-independent effects (for example, alter-
ation of RNA secondary structure, mRNA stability, or disruption
of a binding site for some unknown regulatory factor). However,
the previously reported miR-155-deficient mouse also showed
upregulated AID expression (though to a lesser degree than
observed in our Aicda-Gfp-Mut mouse, to be discussed below)
(Vigorito et al., 2007), and we believe that the phenotypes ob-
served in the Aicda-Gfp-Mut mouse are explained by a model
in which miR-155 directly regulates AID expression. In addition,
AID expression is stringently regulated in B cells such that mice
heterozygous for Aicda show clear signs of haploinsufficiency
(data not shown). These observations together with our results
suggest that, especially when protein amounts are already limit-
ing, a single miRNA can contribute far more substantially to
control of protein expression than previously appreciated.
Ablating miR-155 control of AID expression led to increased
protein expression in switching cells, which undergo significantly
higher levels of CSR. It also led to increased protein expression
in germinal-center cells. However, increased AID expression did
not lead to more SHM in the Ig locus, in accordance with previ-
ous work by the Honjo group (Muto et al., 2006), whose members
have shown that transgenic AID overexpression does not lead
to an increase in SHM. Our data presented here, and the data
published by Muto et al., support the notion of the existence of
a limiting factor that targets AID to the Ig locus so that, in its pres-
ence, excess AID cannot access the locus (though in its absence
it can, possibly in a stochastic fashion).
Excess AID in germinal-center cells, however, appears to
increase hypermutation in other loci, such as Bcl6, which are
known secondary targets of the SHM apparatus. Excess AID is
also likely to increase the rates of chromosomal translocations
associated with errant hypermutation (Ramiro et al., 2006; Ram-
iro et al., 2004) (also, see Dorsett et al., 2008, in this issue). There-
fore, lack of miR-155 control of AID expression might be causal
for B cell lymphomagenesis. Indeed, Kluiver et al. have recently
documented a lack of miR-155 expression in primary cases of
B cell Burkitt’s lymphomas, which constitutively express AID
(Kluiver et al., 2006).
In addition to overabundance of AID, we find that lack of
miR-155 control leads to persistence of AID expression in
post-germinal-center B cells, thus effectively marking a unique
subset of circulating B cells as recent emigrants from the germi-
nal center. We also find that persistent AID expression is associ-
ated with specific defects in affinity maturation. It is possible that
persistent AID expression supports ongoing mutation in the Ig
locus well after cells exit the germinal center with an affinity-ma-
tured antigen receptor and thus effectively destroys the properly
selected antigen-specific Ig repertoire. However, this scenario
is not strongly supported by our data, emphasizing again that
specific cofactors might be required to target AID to the Ig locus.
Instead, we observe multiple low-affinity B cell clones in the blood
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miR-155 Negatively Regulates AIDof animals for which the AID gene is not subject to miR-155 con-
trol, suggesting a defect in positive selection of properly matured
B cells. Although the mechanisms of positive selection and affin-
ity maturation are not well understood, it is thought that B cells cy-
cle between the dark zone of the germinal center, where mutation
occurs, and the light zone, where their newly minted receptors are
substrates for positive selection. Eventually, high-affinity B cells
are thought to emerge after multiple rounds of recycling through
the germinal center. Our data support a scenario where B cells
overexpressing AID might not be allowed to ‘‘recycle’’ into a
germinal center for proper affinity maturation. We could specu-
late on the existence of a mechanism for cellular sensing of AID
expression that would form a feedback loop between proper
AID extinction and GC cycling. However, this would be difficult
to experimentally demonstrate because little is presently known
about the cellular and molecular parameters governing the
mechanism of proper selection and affinity maturation.
The previously described miR-155-deficient mouse models
(Rodriguez et al., 2007; Thai et al., 2007) highlighted the immense
contribution of miR-155-mediated regulation to various aspects
of vertebrate immunity. The phenotypes therein—specifically,
a modest increase in AID expression, decreased in vivo CSR
to IgG1, and impaired affinity maturation—probably reflect the
composite deregulation of at least 60 genes (Vigorito et al.,
2007). In contrast to global ablation of miR-155 regulation, we
describe here specific disruption of a single miR-155: target in-
teraction. In our mouse model, we observed robust deregulation
of AID-GFP expression, increased in vitro CSR, and impaired af-
finity maturation, effects that might not be apparent in the more
complex context of total miR-155 deficiency.
As the central catalyst for antibody diversification processes,
AID has been shown to be regulated at the point of transcription
(Dedeoglu et al., 2004; Gonda et al., 2003; Sayegh et al., 2003),
by nucleo-cytoplasmic trafficking (Ito et al., 2004; McBride et al.,
2004), and by phosphorylation (Basu et al., 2005; Basu et al.,
2007; McBride et al., 2006; Pasqualucci et al., 2006). Here we re-
veal an additional miRNA-mediated pathway of AID regulation,
which controls AID expression in germinal-center B cells and
ensures proper extinction of AID expression as cells undergo af-
finity maturation and exit the secondary lymphoid organs. Thus,
miR-155 plays an important role in the molecular restraint of AID,
an enzyme that confers great immunological benefit but whose
mutagenic potential must limited by tight regulation.
EXPERIMENTAL PROCEDURES
B Lymphocyte Isolation and Cell Culture
CD43– naive splenic B lymphocytes were purified by magnetic separation
(MACS, Miltenyi Biotec). Cells were maintained at 0.5 3 106–1 3 106 cells/ml
in standard culture medium and were treated with 5 ng/ml IL-4 (Sigma) and
25 mg/ml LPS (Sigma) so that CSR would be induced to IgG1; with 25 mg/ml
LPS for induction of CSR to IgG3; or with 25 mg/ml LPS and 0.5 mg/ml IFNg
(Sigma) so that CSR would be induced to IgG2a. CH12-F3 cells were main-
tained in standard culture medium and were treated with 5 ng/ml IL-4,
0.2 mg/ml anti-CD40 (eBioscience), and 0.1 ng/ml TGF-b (R&D Systems) so
that CSR would be induced to IgA. Cell cultures were sampled at various
time points for FACS analysis or preparation of RNA.
RNA Isolation and Small RNA Cloning
TotalRNA was preparedwith Trizol (Invitrogen), and 21–23 ntRNAs were isolated,
cloned,sequenced,andcatalogedaspreviouslydescribed(Landgrafetal., 2007).RNA Blots
Total RNA (10–20 mg) was run on a 15% TBE-urea criterion gel (Bio-Rad)
and transferred to a Hybond N+ nylon membrane (Amersham Biosciences)
by semi-dry blotting. Membranes were UV-crosslinked and dried. A miR-155
probe (50-ACCCCTATCACAATTAGCATTAA-30) was prepared by T4 polynu-
cleotide kinase labeling with g32P-ATP. Blots were hybridized in Denhardt’s
solution or QuickHyb (Stratagene) at 50C and were washed twice with wash
solution I (5% SDS, 53SSC) and twice with wash solution II (1% SDS, 13SSC).
Luciferase Assays
Reporter constructs were modified from the pRL-TK plasmid (Promega). The
renilla luciferase gene was replaced by firefly luciferase (fLuc) for creation of
the Luc construct. The 30 UTR of the AID mRNA was cloned directly down-
stream of fLuc to create the Luc-UTR plasmid. This was then altered by Quik-
change PCR (Stratagene) for creation of the Luc-UTR-Del and Luc-UTR-Mut
constructs. CH12-F3 cells were cotransfected with a reporter construct and
pRL-TK by Amaxa nucleofection and were stimulated for CSR as above. Cells
were lysed 48 hr after transfection, and the Dual Luciferase Reporter Assay Sys-
tem (Promega) was used for measuring firefly and renilla luciferase activities.
CSR Rescue by AID-GFP
Replication-deficient retroviruses were generated by transfection of 293T cells
with either AID-GFP-pQCXIP or pQCXIP alone, along with pCL-Eco packaging
plasmid. Viral stocks were used to transduce naive splenic B lymphocytes
from Aicda/ mice, which had been stimulated in culture with IL-4 and LPS.
Transgenic Mice
The Aicda-Gfp-Mut BAC was modified from the Aicda-Gfp BAC used for cre-
ating the previously described Aicda-Gfp reporter mouse (Crouch et al., 2007)
(copy number ranging from 1–10). Mutation of the miR-155 target site was
achieved by homologous recombination in bacteria as described previously
(Misulovin et al., 2001). In brief, the AID miR-155 target site plus approximately
1 kb flanking sequence on either side (for homologous recombination) was am-
plified by PCR from BAC RP24-68I7 (GenBank AC158651) with primers
50-GGCGCGCCGGTAAGTCTGCCTGTCTGTCTGCC-30 and 50-GCGGCCGC
GCGTCATTTCCTTGCCACGG-30. The PCR product was cloned into TOPO-
pCR4 (Invitrogen). Point mutations in the miR-155 target site were introduced
by Quikchange PCR (Stratagene). The sequence was again amplified with the
same primers as above and cloned into shuttle vector pLD53.SC.AEB (which
also contains the RecA and SacB genes). After propagation in PIR2 bacteria
(Invitrogen), the construct was electroporated into bacteria carrying the previ-
ously described modified BAC RP24-68I7 containing the Aicda-Gfp locus
(Crouch et al., 2007). Cointegrates were selected for in liquid culture in the
presence of ampicillin (for the insert-containing shuttle vector) and chloram-
phenicol (for the BAC), during which RecA-mediated recombination occurred
between the BAC and homologous sequences inserted into the shuttle vector.
Cultures were plated on chloramphenicol, and the desired recombination
event (introduction of the modified miR-155 target site into BAC and deletion
of the shuttle vector sequence) was ensured by treatment of duplicate plates
with UV illumination and sucrose so that the loss of the shuttle-vector-encoded
RecA and SacB, respectively, would be ensured. The integrity of the newly
generated Aicda-Gfp-Mut locus was confirmed by sequencing. Generation
of the Aicda-Gfp-Mut transgenic founder mice (copy number ranging from
5–20) was performed by the Rockefeller University Transgenic Services Labo-
ratory according to standard methods. Transgene copy numbers were
estimated by comparison to copy-number standards in Southern analysis.
Animals were housed and studied in accordance with institutional guidelines.
Quantitative PCR
cDNA was generated from DNase-I-treated RNA, and AID-GFP expression
was monitored by quantitative PCR (50-GACTTGCGAGATGCATTTCGTATG-30
and 50-GCTGAACTTGTGGCCGTTTAC-30). cDNA samples were normalized
by amplification of Ku70 (50-TGCCCTTTACTGAGAAGGTGAC-30 and 50- TGCT
GCAGGACTGGATTCTC-30).
Immunization and ELISA
Mice were immunized with 100 mg alum-precipitated NP-CGG (Biosearch
Technologies) by intraperitoneal injection. Serum was prepared from peripheralImmunity 28, 621–629, May 2008 ª2008 Elsevier Inc. 627
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were incubated in NP3-BSA or NP30-BSA-coated wells of microtiter plates,
and NP-specific Ig was detected by ELISA with reagents from Southern
Biotechnologies Clonotyping System-HRP. Affinity maturation was calculated
as the ratio of NP3 binding (high-affinity anti-NP Ig) to NP30 binding (total
anti-NP Ig).
FACS Analysis
Cell suspensions from bone marrow, spleen, Peyer’s patches, thymus, and
peripheral blood were prepared and stained for FACS according to standard
procedures. The following reagents were used for staining cells for FACS anal-
ysis (all are from BD Biosciences except where indicated): CD93-PE (eBio-
science), IgM-APC (Jackson Immunoresearch), CD95-PE-Cy7, B220-PerCP,
B220-APC, IgG1-biotin, IgM-biotin, IgD-biotin (eBioscience), CD8-PerCP,
CD4-APC, NP-PE (Biosearch Technologies), and Streptavidin-PerCP.
Mutational Analysis
Genomic DNA was prepared from sorted splenic germinal-center B cells and
white blood cells from peripheral blood. The following were amplified by PCR
with PfuTURBO polymerase (Stratagene): JH4 intron (50-AGCCTGACATCTGA
GGAC-30 and 50-TAGTGTGGAACATTCCTCAC-30, annealing temperature
55C for 35 cycles; followed by a nested reaction, 50-CTGACATCTGAGGACTC
TGC-30 and 50-GCTGTCACAGAGGTGGTCCTG-30, annealing temperature
58C for 35 cycles); VH186.2 (50-TCTTTACAGTTACTGAGCACACAGGAC
and 50-GGGTCTAGAGGTGTCCCTAGTCCTTCATGACC, annealing tempera-
ture 50C for 35 cycles; followed by a nested reaction, 50-CAGTAGCAGGCTT
GAGGTCTGGAC-30 and 50-GGGTCTAGAGGTGTCCCTAGTCCTTCATGAC
C-30, annealing temperature 64C for 35 cycles);bcl-6 (50-GGCCGGACACCAG
GTGATTAT-30 and 50-AGGGAGGGAACTACCGCTGAG-30, annealing temper-
ature 68C for 35 cycles).
PCR products were blunt-end cloned into pSC-B (Stratagene) and
sequenced with a standard T3 primer.
SUPPLEMENTAL DATA
Three figures are available with this article online at http://www.immunity.com/
cgi/content/full/28/5/621/DC1/.
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